The worldwide rising prevalence of obesity and insulin resistance is associated with a
parallel increase in nonalcoholic fatty liver disease (NAFLD). NAFLD is characterized by …

Adipose tissue is now recognized as an important endocrine organ, capable of secreting a
large number of endocrine factors which regulate a wide variety of physiological functions …

Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of disease ranging from
hepatocellular steatosis through steatohepatitis to fibrosis and irreversible cirrhosis. The …

Chronic nonalcoholic steatohepatitis (NASH) is a metabolic disorder that often leads to liver
fibrosis, a condition with limited therapy options. Adiponectin is an adipocytokine that …

High dietary fructose is a major contributor to insulin resistance and metabolic syndrome,
disturbing tissue and organ functions. Fructose is mainly absorbed into systemic circulation …

In 1980, Ludwig and colleagues described a series of patients with liver histology
characterized by the accumulation of fat and the presence of hepatic necroinflammation in …

Nonalcoholic steatohepatitis (NASH), a common clinical disease, is becoming a leading
cause of hepatocellular carcinoma (HCC). Dual specificity phosphatase 22 (DUSP22, also …

Adipokines are polypeptides secreted in the adipose tissue in a regulated manner. While
some of these molecules are expressed only by adipocytes, resident and infiltrating …

Non-alcoholic fatty liver disease (NAFLD) comprising hepatic steatosis, non-alcoholic
steatohepatitis (NASH), and progressive liver fibrosis is considered the most common liver …

Non-alcoholic fatty liver disease is the clinical hepatic expression of metabolic syndrome.
The prevalence of non-alcoholic fatty liver disease is around 20–30%, and with a rapid …